"Hordes of cash by Big Pharma and the larger bioetch companies have
accumulated, and now that health care reform is behind us, they've
got a bit more confidence and they want to fill in their pipeline
and be in control of the FDA process," says Joel Papernik, a
partner of Mintz Levin in The Deal's video. "They have a lot of
motivation to buy right now," including the expiration of many
patents, he says. The interview with Papernik is part of our
special series on Faces of the Middle Market. Read the full story
in The Deal magazine, watch the videos, listen to the podcasts and
read the white papers. Watch the interview with Papernik below or
download it on iTunes. . -- Mary Kathleen Flynn

Executive Producer: Tom Groppe

Producer: Maria Woehr

Writers: Nathaniel Baker, Mary Kathleen Flynn and Chris
Nolter

Camera: George White

Editing: George White and Vipal Monga

Sound: Maria Woehr

Art and Photos: Chris Kwieraga, Linda Peng and Neil
Buchalter

Copyeditor: Alexander Dering

Also see:
Garrett Baker on cable M&A
Updata Advisors' Ira Cohen on tech M&A
Jordan Edmiston's Scott Peters on media M&A
Manatt Phelps' Jay Rand on tech M&A

If you have questions, suggestions or would like to appear on
Deal Video please contact Maria Woehr at mwoehr@thedeal.com.